Regulated gene editing system
A gene and editing technology, applied in the field of regulating gene editing compositions, can solve off-target and other problems
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0404] Example 1. Differential regulation of multiple transgenes in AAV vectors by alternative splicing
[0405] introduce
[0406] Wild-type AAV is a non-pathogenic, non-enveloped, small single-stranded DNA virus with a genome of 4.7 kb in length. Recombinant AAVs have been developed and used as gene therapy vectors for decades. The ability to regulate transgene expression is critical to ensuring the safety of many gene therapy strategies. Several strategies for controlling transgene expression (eg tet-on or rapamycin-inducible systems) have been tested for AAV vector-mediated gene transfer. Each regulatory system has advantages and disadvantages depending on the target to be treated. As a strategy to develop a transgenic regulatory system that simplifies the gene delivery system, eliminates immune responses against transactivators, and induces the induction of AAV-mediated gene delivery by adapting the splicing-switching mechanism of the IVS2-654 intron Multiple transgen...
Embodiment 2
[0438] Example 2. Generation of saCas9 comprising regulatory nucleic acid sequences
[0439] As described in Example 1, saCas9 containing regulatory sequences (beta globin intron regions) was generated. The regulatory sequence intron region (eg, SEQ ID NO: 53 (IVS2-654 intron with a 200 bp deletion) was subcloned into an AAV vector plasmid carrying saCas 9 using restriction digestion.
Embodiment 3
[0440] Example 3. Assay for off-target effects of gene editing
[0441] Sequencing of digested genomes (Digenome-seqover), an in vitro Cas9 digested whole-genome sequencing, is a robust, sensitive, unbiased, and cost-effective method for analyzing programmable nucleases (e.g., Cas9) in mammals ( Genome-wide off-target effects in human cells).
[0442] HeLa, HEK, and CHO cells expressing Nav 1.8-directed gRNAs were transfected using lipofectamine 2000 (Life Technologies) with: (1) nuclease-free (eg, untransfected population); (2) constitutively active Casp 9; (3) a gene editing system described herein that does not contain an oligonucleotide that binds a regulatory sequence, such as a nuclease in an "OFF" position; and (4) a gene editing system described herein and Oligonucleotides that bind regulatory sequences, eg, nucleases in the "ON" position. HeLa cells were cultured in DMEM medium containing 10% FBS. Cells were cultured for 48 hours.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


